More recently, evinacumab, an inhibitor of angiopoietin-like 3 (ANGPTL3), has shown the capacity to reduce LDLc significantly, even in homozygotes for familial hypercholesterolemia [71]. Here, ANGPTL3 is linked to familial hypercholesterolemia.